ChinaNationalAccordMedicinesCorporationLtd.
FirstQuarterlyReport2020
April2020
SectionI.ImportantNotes
BoardofDirectorsandtheSupervisoryCommitteeofChinaNationalAccordMedicinesCorporationLtd.(hereinafterreferredtoastheCompany)anditsdirectors,supervisorsandseniorexecutivesshouldguaranteethereality,accuracyandcompletionofthequarterlyreport,therearenoanyfictitiousstatements,misleadingstatementsorimportantomissionscarriedinthisreport,andshalltakelegalresponsibilities,individualand/orjoint.AllDirectorsareattendedtheBoardMeetingforQuarterlyReportdeliberation.LinZhaoxiongpersoninchargeoftheCompany,WeiPingxiao,personinchargerofaccountingworksandWangYing,personinchargerofaccountingorgan(accountingofficer)herebyconfirmthattheFinancialReportofthisQuarterlyReportisauthentic,accurateandcomplete.
SectionII.CompanyprofileI.Mainaccountingdataandfinancialindexes
Whetherithasretroactiveadjustmentorre-statementonpreviousaccountingdata
√Yes□NoRetrospectiveadjustmentorrestatementreasonsBusinesscombinationunderthesamecontrol
| CurrentPeriod | Sameperiodoflastyear | Changesofthisperiodoversameperiodoflastyear | ||
| Beforeadjustment | Afteradjustment | Afteradjustment | ||
| Operatingincome(RMB) | 12,824,196,278.66 | 11,879,309,078.82 | 12,071,656,553.13 | 6.23% |
| Netprofitattributabletoshareholdersofthelistedcompany(RMB)(note1) | 248,800,655.88 | 300,149,012.08 | 299,451,036.34 | -16.91% |
| Netprofitattributabletoshareholdersofthelistedcompanyafterdeductingnon-recurringgainsandlosses(RMB) | 241,724,850.95 | 297,420,355.99 | 297,420,355.99 | -18.73% |
| Netcashflowarisingfromoperatingactivities(RMB) | -688,273,848.63 | -759,367,352.29 | -788,378,287.50 | 12.70% |
| Basicearningspershare(RMB/Share)(note1) | 0.58 | 0.70 | 0.70 | -17.14% |
| Dilutedearningspershare(RMB/Share) | 0.58 | 0.70 | 0.70 | -17.14% |
| WeightedaverageROE(note1) | 1.92% | 2.55% | 2.52% | 0.60percentagepointdown |
| Attheendofthereportingperiod | Attheendoflastyear | Changesofthisperiod-endoversameperiod-endoflastyear | ||
| Beforeadjustment | Afteradjustment | Afteradjustment | ||
| Totalassets(RMB) | 36,882,640,680.62 | 30,855,284,546.74 | 34,030,520,217.82 | 8.38% |
| Netassetsattributabletoshareholderoflistedcompany(RMB) | 13,062,640,261.41 | 11,918,581,615.36 | 12,911,706,424.61 | 1.17% |
Descriptiononretrospectiveadjustment:
Inthisyear,theCompanyacquired75%equityofPudongNewAreaofShanghaiPharmaceuticalMedicineLtd.underthesamecontrol.WhenpreparingthecomparativestatementoftheconsolidatedstatementforQ1of2020,thepartiesinvolvedinthemergershallberegardedasexistinginthecurrentstatewhenthefinalcontrollingpartystartstoimplementthecontrol,andthepreliminarycomparativestatementshallbeadjusted.Note1:Netprofitattributabletoshareholdersofthelistedcompanyhas16.91%downcomparedwithsameperiodlastyear,mainly
becauseaffectedbytheCOVID-19epidemic,salesgrowthoftheCompanysloweddowninthefirstquarter,atthesametime,changesinindustrypoliciesalsoledtoanarrowingofprofitmargins;whilethebasicEPSdecreasedby17.14%correspondingly.WeightedaverageROEhas0.60percentagepointsdowncomparedwithsameperiodlastyear.Itemsofnon-recurringgainsandlosses
√Applicable□Notapplicable
InRMB
| Item | Amountfromyear-begintoperiod-end | Note |
| Gains/lossesfromthedisposalofnon-currentasset(includingthewrite-offthataccruedforimpairmentofassets) | -438,158.53 | Mainlyforstorerent-outandfixedassetdisposallosses. |
| Governmentalsubsidyreckonedintocurrentgains/losses(notincludingthesubsidyenjoyedinquotaorrationaccordingtonationalstandards,whicharecloselyrelevanttoenterprise’sbusiness) | 13,645,696.75 | MainlyduetotheTaxreliefandvariousspecialgrantsreceivedinthecurrentperiod. |
| Switchbackofprovisionfordepreciationofaccountreceivableandcontractassetsthatareindividuallytestedforimpairment | 72,938.17 | |
| Consigningfeereceivedforconsignedoperation | 961,488.75 | |
| Othernon-operatingincomeandexpenditureexceptfortheaforementioneditems | -491,478.52 | |
| Othergains/lossessatisfyadefinitionofextraordinarygains/losses | 257,186.89 | |
| Less:Impactonincometax | 3,271,286.58 | |
| Impactonminorityshareholders’equity(post-tax) | 3,660,582.00 | |
| Total | 7,075,804.93 | -- |
Concerningtheextraordinaryprofit(gain)/lossdefinedbyQ&AAnnouncementNo.1onInformationDisclosureforCompaniesOfferingTheirSecuritiestothePublic---ExtraordinaryProfit/loss,andtheitemsdefinedasrecurringprofit(gain)/lossaccordingtothelistsofextraordinaryprofit(gain)/lossinQ&AAnnouncementNo.1onInformationDisclosureforCompaniesOfferingTheirSecuritiestothePublic---ExtraordinaryProfit/loss,explainreasons
□Applicable√NotapplicableInreportingperiod,theCompanyhasnoparticularaboutitemsdefinedasrecurringprofit(gain)/lossaccordingtothelistsofextraordinaryprofit(gain)/lossinQ&AAnnouncementNo.1onInformationDisclosureforCompaniesOfferingTheirSecuritiestothePublic---ExtraordinaryProfit/loss
II.Totalnumberofshareholdersattheendofthisreportperiodandtoptenshareholders
1.Totalnumberofcommonshareholdersattheendofthisreportperiodandtoptencommonshareholders
Inshares
| Totalcommonshareholdersattheendofreportperiod | 26,399 | Totalpreferenceshareholderswithvotingrightsrecoveredat | 0 |
| endofreportingperiod(ifapplicable) | ||||||||
| Toptenshareholders | ||||||||
| Shareholder’sname | Natureofshareholder | Proportionofsharesheld | Amountofsharesheld | Amountofrestrictedsharesheld | Numberofsharepledged/frozen | |||
| Stateofshare | Amount | |||||||
| SinopharmGroupCo.,Ltd. | State-ownedlegalperson | 56.06% | 239,999,991 | 5,505,770 | ||||
| HongKongSecuritiesClearingCompanyLtd | ForeignCorporation | 4.55% | 19,472,330 | |||||
| HTHK/CMGFSGUFP-CMGFIRSTSTATECHINAGROWTHFD | ForeignCorporation | 2.68% | 11,469,644 | |||||
| NationalSocialSecurityFund-portfolio118 | Domesticnonstate-ownedCorporation | 1.82% | 7,774,799 | |||||
| ChinaNationalPharmaceuticalForeignTradeCorp. | State-ownedCorporation | 1.24% | 5,323,043 | |||||
| FidelityInvestmentManagement(HongKong)Limited-Client’sfund | ForeignCorporation | 1.09% | 4,668,607 | |||||
| CentralHuijinInvestmentLtd. | State-ownedCorporation | 0.89% | 3,804,400 | |||||
| BBHBOSS/AFIDELITYFD-CHINAFOCUSFD | ForeignCorporation | 0.78% | 3,358,761 | |||||
| BankofChinaCo.,Ltd.-HarvestHealthcareEquitySecuritiesInvestmentFund | Domesticnonstate-ownedCorporation | 0.67% | 2,862,997 | |||||
| Basicendowmentinsurancefund-portfolio15061 | Domesticnonstate-ownedCorporation | 0.55% | 2,364,393 | |||
| Toptenshareholderswithunrestrictedsharesheld | ||||||
| Shareholder’sname | Amountofunrestrictedsharesheld | Typeofshares | ||||
| Type | Amount | |||||
| SinopharmGroupCo.,Ltd. | 234,494,221 | RMBordinaryshares | 234,494,221 | |||
| HongKongSecuritiesClearingCompanyLtd | 19,472,330 | RMBordinaryshares | 19,472,330 | |||
| HTHK/CMGFSGUFP-CMGFIRSTSTATECHINAGROWTHFD | 11,469,644 | Domesticlistedforeignshares | 11,469,644 | |||
| NationalSocialSecurityFund-portfolio118 | 7,774,799 | RMBordinaryshares | 7,774,799 | |||
| ChinaNationalPharmaceuticalForeignTradeCorp. | 5,323,043 | RMBordinaryshares | 5,323,043 | |||
| FidelityInvestmentManagement(HongKong)Limited-Client’sfund | 4,668,607 | RMBordinaryshares | 4,668,607 | |||
| CentralHuijinInvestmentLtd. | 3,804,400 | RMBordinaryshares | 3,804,400 | |||
| BBHBOSS/AFIDELITYFD-CHINAFOCUSFD | 3,358,761 | Domesticlistedforeignshares | 3,358,761 | |||
| BankofChinaCo.,Ltd.-HarvestHealthcareEquitySecuritiesInvestmentFund | 2,862,997 | RMBordinaryshares | 2,862,997 | |||
| Basicendowmentinsurancefund-portfolio15061 | 2,364,393 | RMBordinaryshares | 2,364,393 | |||
| Explanationonassociatedrelationshipamongtheaforesaidshareholders | ItisunknownthatthereexistsnoassociatedrelationshiporbelongstotheconsistentpersonactinginconcertamongtheothertradableshareholdersregulatedbytheManagementMeasureofInformationDisclosureonChangeofShareholdingforListedCompanies. | |||||
Whethertoptencommonshareholdersortoptencommonshareholderswithun-restrictsharesheldhaveabuy-backagreementdealinginreportingperiod
□Yes√NoThetoptencommonshareholdersortoptencommonshareholderswithun-restrictsharesheldoftheCompanyhavenobuy-backagreementdealinginreportingperiod.
2.TotalshareholderswithpreferredstockheldatPeriod-endandsharesheldbytoptenshareholderswithpreferredstockheld
□Applicable√Notapplicable
SectionIII.SignificantEventsI.Particularsaboutmaterialchangesinitemsofmainaccountingstatementandfinancialindexandexplanationsofreasons
√Applicable□Notapplicable
1.Notesreceivable:adecreaseof264.6581millionYuancomparedwiththebeginningoftheperiod,withagrowthrateof-33.59%,mainlybecauseaffectedbytheGPOpolicy,thehospitalcustomerprocurementmodelhaschanged,andthesettlementmethodhasalsochanged;
2.Advancestosuppliers:anincreaseof387.3169millionYuancomparedwiththebeginningoftheperiod,withagrowthrateof
99.36%,mainlybecausetheprepaymentofemergencyspecialreservematerialsforthepreventionandcontrolofCOVID-19andtheincreaseintheprepaymentsdueontheimportletterofcredit;
3.Dividendreceivable:adecreaseof834,914.61Yuancomparedwiththebeginningoftheperiod,withagrowthrateof-100.00%,mainlybecausedividendsreceivablefromShanghaiDingqunEnterpriseManagementConsultingCo.,Ltd.inthesameperiodoflastyear,thiscompanyhasbeenincludedinthescopeofconsolidationintheperiod,andthereisnobalanceattheconsolidationlevelafterinternaloffset;
4、Intangibleassets:anincreaseof260.2451millionYuancomparedwiththebeginningoftheperiod,withagrowthrateof69.37%,mainlybecausethesalesnetworknewlyrecognizedintheperiodfortheacquisitionofShanghaiDingqunEnterpriseManagementConsultingCo.,LtdbysubsidiaryGuodaDrugstore;
5.Goodwill:anincreaseof503.1178millionYuancomparedwiththebeginningoftheperiod,withagrowthrateof49.81%,mainlyresultedbytheacquisitionofShanghaiDingqunEnterpriseManagementConsultingCo.,LtdbysubsidiaryGuodaDrugstoreintheperiod;
6.Othernon-currentassets:anincreaseof336.7663millionYuancomparedwiththebeginningoftheperiod,withagrowthrateof
435.35%,mainlybecauseinordertopreventingandcontrollingtheCOVID-19,topurchaseemergencyspecialreservematerialsattherequestofthegovernment;
7.Short-termborrowings:anincreaseof1,332.2357millionYuancomparedwiththebeginningoftheperiod,withagrowthrateof
91.69%,mainlybecausethesupplychainfinancingandspecialloansforpreventionandcontroloftheCOVID-19epidemicareincreasedinthePeriod;
8.Otherpayables:anincreaseof874.467millionYuancomparedwiththebeginningoftheperiod,withagrowthrateof47.99%,mainlyduetotheequityconsiderationpayableforacquisitionofShanghaiDingqunEnterpriseManagementConsultingCo.,LtdbysubsidiaryGuodaDrugstoreintheperiodandthenon-financialinstitutionfundsborrowing;
9.Dividendpayable:anincreaseof37.9886millionYuancomparedwiththebeginningoftheperiod,withagrowthrateof594.56%,mainlyduetothedividendpayabletooriginalshareholdersofShanghaiDingqunEnterpriseManagementConsultingCo.,Ltd.-thesubsidiaryoftheCompanythatincludedintheconsolidatescopeinthePeriod;10、Deferredtaxliabilities:anincreaseof61.9156millionYuancomparedwiththebeginningoftheperiod,withagrowthrateof
52.16%,mainlybecausethevalue-addedforfairvalueoftheassetsgeneratedfromacquisitionofShanghaiDingqunEnterpriseManagementConsultingCo.,LtdbyGuodaDrugstoreinthePeriod,arerecognizedtocorrespondingthedeferredincometaxliability;
11.Othernon-currentliabilities:anincreaseof318.5282millionYuancomparedwiththebeginningoftheperiod,withagrowthrateof434.81%,mainlyduetotheadvancepaymentforpurchasingthegovernmentemergencyspecialreservematerialsinpreventionandcontrollingtheCOVID-19epidemic;
12.Financecosts:anincreaseof13.411millionYuanonayear-on-yearbasis,withagrowthrateof85.97%,mainlyduetothe
implementationofnewleasingstandards;
13.Impairmentlosses:anincreaseof1.0819millionYuanonayear-on-yearbasis,withagrowthrateof209.44%,mainlybecausetheprovisionforinventorydeclineinpricesinthecurrentperiodincreasedonay-o-ybasis;
14.Creditimpairmentlosses:anincreaseof12.4452millionYuanonayear-on-yearbasis,withagrowthrateof282.86%,mainlybecausetheendingaccountreceivableincreasedfromayearearlierfortheexpansionofsalesscale,andatthesametime,affectedbyCOVID-19epidemic,theturnoverdaysofreceivableshaveincreased,andtheprovisionforbaddebtshaveincreasedaccordingly.
15.Otherincomes:anincreaseof12.0434millionYuanonayear-on-yearbasis,withagrowthrateof1,105.17%,mainlybecausetheincreaseofTaxreliefandvariousspecialgrantsreceivedinthisperiod;
16.Investmentincome:adecreaseof22.707millionYuanonayear-on-yearbasis,withagrowthrateof-34.73%,mainlybecausetheinvestmentincomefromassociatesdeclinedfromayearearlier;
17.Gainondisposalofassets:adecreaseof247,055.53Yuanonayear-on-yearbasis,withagrowthrateof-1,738.69%,mainlyduetothelossfromsurrenderofretailpremisesforimplementingthenewleasingstandard,whilenosuchmatteroccurredlastyear;
18.Non-operatingexpenses:anincreaseof1.3356millionYuanonayear-on-yearbasis,withagrowthrateof356.39%,mainlyduetotheincreaseinfinesinthisperiod;
19.Othercashreceiptsrelatingtooperatingactivities:anincreaseof295.9483millionYuanonayear-on-yearbasis,withagrowthrateof215.29%,mainlyduetothereceiptofspecialreservefundsforthepreventionandcontroloftheCOVID-19,nosuchmatterinthesameperiodoflastyear;
20.Cashreceivedfromreturnsoninvestments:adecreaseof1.053millionYuanonayear-on-yearbasis,withagrowthrateof-100.00%,mainlybecausereceivedcashdividendsfromassociatesinthesameperiodoflastyear,whilenosuchmatterintheperiod;
21.Netcashreceivedfromdisposaloffixedassets,intangibleassetsandotherlong-termassets:anincreaseof35,352.18Yuanonayear-on-yearbasis,withagrowthrateof49.05%,mainlyduetotheincreaseincashreceivedfromthedisposaloffixedassetsduringtheperiod;
22.Othercashreceiptsrelatingtoinvestingactivities:adecreaseof166.5millionYuanonayear-on-yearbasis,withagrowthrateof-88.33%,mainlybecauseintheperiod,thePudongNewAreaofShanghaiPharmaceuticalMedicineLtdwasmergedbysubsidiaryGuodaDrugstoreunderthesamecontrol,andreceivedanaccountfromthecashpoolofformerparentcompany-SinopharmGroupCo.,Ltd,andrecoverthefundoriginallycollectedinthecashpoolintheperiod;
23.Sub-totalofcashinflowsfrominvestingactivities:adecreaseof167.5176millionYuanonayear-on-yearbasis,withagrowthrateof-88.34%,mainlybecauseintheperiod,thePudongNewAreaofShanghaiPharmaceuticalMedicineLtdwasmergedbysubsidiaryGuodaDrugstoreunderthesamecontrol,andreceivedanaccountfromthecashpoolofformerparentcompany-SinopharmGroupCo.,Ltd,andrecoverthefundoriginallycollectedinthecashpoolintheperiod;
24.Cashpaymentsforinvestments:adecreaseof8.781millionYuanonayear-on-yearbasis,withagrowthrateof-43.64%,mainlybecausethetransferamountpaidforretailstoreacquisitionbysubsidiaryGuodaDrugstoredeclinedfromayearearlier;
25.Netcashpaidforacquisitionofsubsidiariesandotherbusinessunits:anincreaseof664.8827millionYuanonayear-on-yearbasis,withagrowthrateof100%,mainlyduetothenetcashpaidforacquisitionofShanghaiDingqunEnterpriseManagementConsultingCo.,LtdfromsubsidiaryGuodaDrugstore,andnosuchmatterinthesameperiodoflastyear;
26.Othercashpaymentsrelatingtoinvestingactivities:adecreaseof116.5382millionYuanonayear-on-yearbasis,withagrowthrateof-73.80%,mainlybecauseintheperiod,thePudongNewAreaofShanghaiPharmaceuticalMedicineLtdwasmergedbysubsidiaryGuodaDrugstoreunderthesamecontrol,thecashpoolwascollectedtoformerparentcompany-SinopharmGroupCo.,Ltd,whilenosuchmatterintheperiod;
27.Sub-totalofcashoutflowsfrominvestingactivities:anincreaseof535.6961millionYuanonayear-on-yearbasis,withagrowthrateof230.80%,mainlyduetothenetcashpaidforacquisitionofShanghaiDingqunEnterpriseManagementConsultingCo.,LtdfromsubsidiaryGuodaDrugstore,andnosuchmatterinthesameperiodoflastyear;
28.Netcashflowsfrominvestingactivities:adecreaseof703.2137millionYuanonayear-on-yearbasis,withagrowthrateof-1,655.61%,mainlyduetothenetcashpaidforacquisitionofShanghaiDingqunEnterpriseManagementConsultingCo.,Ltdfrom
subsidiaryGuodaDrugstore,andnosuchmatterinthesameperiodoflastyear;
29.Cashproceedsfrominvestmentsbyothers:adecreaseof4.392millionYuanonayear-on-yearbasis,withagrowthrateof-100%,mainlybecausereceivedcapitalincreasefromminorityshareholdersinthesameperiodlastyearwhilenosuchmatterintheperiod;
30.Cashreceivedfromborrowings:anincreaseof276.202millionYuanonayear-on-yearbasis,withagrowthrateof2,762.02%,mainlybecausereceivedspecialloanfundsforthepreventionandcontroloftheCOVID-19inthisperiod,andbankloansincreased;
31.Othercashreceiptsrelatingtofinancingactivities:anincreaseof138.1731millionYuanonayear-on-yearbasis,withagrowthrateof69.48%,mainlybecausethereturnofmoneyorderreceivedintheperiodhasincreasedfromayearearlier,andreceivedfundsborrowedfromnon-financialinstitutions,whilenosuchmatterinthesameperiodoflastyear;
32.Sub-totalofcashinflowsfromfinancingactivities:anincreaseof409.9831millionYuanonayear-on-yearbasis,withagrowthrateof192.23%,mainlybecausereceivedspecialloanfundsforthepreventionandcontroloftheCOVID-19inthisperiod,andthemoneyorderdepositreceivedintheperiodincreasedonay-o-ybasis;
33.Cashrepaymentsfordebts:anincreaseof75.5384millionYuanonayear-on-yearbasis,withagrowthrateof113.49%,mainlyduetotheincreaseinrepaymentofloansintheperiod;
34.Othercashpaymentsrelatingtofinancingactivities:anincreaseof441.6207millionYuanonayear-on-yearbasis,withagrowthrateof1,381.06%,mainlybecauseimplementthenewleasingstandard,andtheinvestmentpaidformergedofPudongNewAreaofShanghaiPharmaceuticalMedicineLtdunderthesamecontrolfromsubsidiaryGuodaDrugstore;
35.Sub-totalofcashoutflowsfromfinancingactivities:anincreaseof497.1017millionYuanonayear-on-yearbasis,withagrowthrateof271.24%,mainlybecauseimplementthenewleasingstandard,andtheinvestmentpaidformergedofPudongNewAreaofShanghaiPharmaceuticalMedicineLtdunderthesamecontrolfromsubsidiaryGuodaDrugstore;
36.Netcashflowsfromfinancingactivities:adecreaseof87.1187millionYuanonayear-on-yearbasis,withagrowthrateof-290.37%,mainlybecauseimplementthenewleasingstandard,andtheinvestmentpaidformergedofPudongNewAreaofShanghaiPharmaceuticalMedicineLtdunderthesamecontrolfromsubsidiaryGuodaDrugstore;
37.Effectofforeignexchangeratechangesoncashandcashequivalents:adecreaseof239.99Yuanonayear-on-yearbasis,withagrowthrateof-39.66%,mainlyduetotheimpactofexchangeratefluctuations;
38.Netincreaseofcashandcashequivalents:adecreaseof690.2282millionYuanonayear-on-yearbasis,withagrowthrateof-86.19%,mainlyduetothenetcashpaidbytheacquisitionofShanghaiDingqunEnterpriseManagementConsultingCo.,Ltd.andtheinvestmentpaymentforthemergerofPudongNewAreaofShanghaiPharmaceuticalMedicineLtdunderthesamecontrolfromsubsidiaryGuodaDrugstore,nosuchmatterinthesameperiodoflastyear.II.Analysisandexplanationofsignificanteventsandtheirinfluenceandsolutions
□Applicable√NotapplicableProgressofsharesbuy-back
□Applicable√NotapplicableImplementationprogressofthereductionofrepurchasessharesbycentralizedbidding
□Applicable√NotapplicableIII.CommitmentscompletedinPeriodandthosewithoutcompletedtillendofthePeriodfromactualcontroller,shareholders,relatedparties,purchaserandcompanies
□Applicable√NotapplicableTheCompanyhasnocommitmentscompletedinPeriodandthosewithoutcompletedtillendofthePeriodfromactualcontroller,shareholders,relatedparties,purchaserandcompanies.
IV.Securitiesinvestment
□Applicable√Notapplicable
NosecurityinvestmentinthePeriod.
V.Trustfinancing
□Applicable√Notapplicable
NotrustfinancinginthePeriod.
VI.Derivativeinvestment
□Applicable√NotapplicableNoderivativeinvestmentinthePeriod.
VII.Registrationformforreceivingresearch,communicationandinterviewinthereportperiod
□Applicable√Notapplicable
TheCompanyhadnoreceivingresearch,communicationorinterviewinthereportperiod.
VIII.Guaranteeoutsideagainsttheregulation
□Applicable√Notapplicable
TheCompanyhadnoguaranteeoutsideagainsttheregulationintheperiod.
IX.Non-operationalfundoccupationfromcontrollingshareholdersanditsrelatedparty
□Applicable√NotapplicableTheCompanyhadnonon-operationalfundoccupationformcontrollingshareholdersanditsrelatedpartyintheperiod.
SectionIV.FinancialStatementI.Financialstatement
1.Consolidatebalancesheet
PreparedbyChinaNationalAccordMedicinesCorporationLtd.
InRMB
| Items | 2020-3-31 | 2019-12-31 |
| Currentassets: | ||
| Cashandbankbalances | 7,343,918,788.98 | 8,885,729,250.47 |
| Settlementprovisions | ||
| Capitallent | ||
| Tradingfinancialassets | ||
| Derivativefinancialassets | ||
| Notesreceivable | 523,366,192.20 | 788,024,326.05 |
| Accountsreceivable | 12,800,950,512.29 | 10,712,983,544.18 |
| Receivablesfinancing | 488,648,048.49 | 451,619,951.05 |
| Advancestosuppliers | 777,145,678.93 | 389,828,785.54 |
| Insurancereceivable | ||
| Reinsurancereceivables | ||
| Contractreserveofreinsurancereceivable | ||
| Otherreceivables | 601,307,772.09 | 501,958,841.43 |
| Including:Interestreceivable | - | - |
| Dividendreceivable | - | 834,914.61 |
| Buyingbackthesaleoffinancialassets | ||
| Inventories | 5,906,648,659.90 | 5,063,274,143.26 |
| Contractualassets | ||
| Assetsheldforsale | ||
| Non-currentassetduewithinoneyear | ||
| Othercurrentassets | 102,839,050.54 | 102,207,498.20 |
| Totalcurrentassets | 28,544,824,703.42 | 26,895,626,340.18 |
| Non-currentassets: | ||
| Loansandpaymentsonbehalf | ||
| Debtinvestment | ||
| Otherdebtinvestment | ||
| Long-termaccountreceivable | ||
| Long-termequityinvestment | 2,148,499,112.76 | 2,105,114,410.88 |
| Otherequityinstrumentinvestment | 116,021,000.00 | 116,021,000.00 |
| Othernon-currentfinancialassets | 140,000,000.00 | 140,000,000.00 |
| Investmentproperties | 137,294,164.25 | 138,900,358.30 |
| Fixedassets | 705,749,195.67 | 709,320,467.92 |
| Constructioninprogress | 22,928,901.67 | 31,582,575.84 |
| Productivebiologicalasset | ||
| Oilandgasasset | ||
| Right-of-useassets | 2,067,046,282.85 | 1,994,757,862.07 |
| Intangibleassets | 635,390,640.10 | 375,145,507.81 |
| ExpenseonResearchandDevelopment | ||
| Goodwill | 1,513,175,733.86 | 1,010,057,927.17 |
| Long-termprepaidexpenses | 359,836,930.28 | 373,527,968.14 |
| Deferredtaxassets | 77,752,777.11 | 63,110,829.12 |
| Othernon-currentasset | 414,121,238.65 | 77,354,970.39 |
| Totalnon-currentasset | 8,337,815,977.20 | 7,134,893,877.64 |
| Totalassets | 36,882,640,680.62 | 34,030,520,217.82 |
| Currentliabilities: | ||
| Short-termborrowings | 2,785,253,982.80 | 1,453,018,300.01 |
| Loanfromcentralbank | ||
| Capitalborrowed | ||
| Tradingfinancialliability | ||
| Derivativefinancialliability | ||
| Notespayable | 4,680,238,916.43 | 5,555,697,557.53 |
| Accountspayable | 7,674,022,927.20 | 6,703,967,826.54 |
| Accountsreceivedinadvance | - | - |
| Contractliabilities | 310,277,865.26 | 303,194,940.70 |
| Sellingfinancialassetofrepurchase | ||
| Absorbingdepositandinterbankdeposit | ||
| Securitytradingofagency | ||
| Securitysalesofagency | ||
| Employeebenefitspayable | 191,026,038.97 | 259,640,813.10 |
| Taxespayable | 215,540,339.83 | 253,379,524.34 |
| Otherpayables | 2,696,831,680.78 | 1,822,364,637.62 |
| Including:Interestpayable | 19,775,863.45 | 23,632,632.90 |
| Dividendpayable | 44,377,935.76 | 6,389,320.96 |
| Commissionchargeandcommissionpayable | ||
| Reinsurancepayable | ||
| Liabilityheldforsale | ||
| Non-currentliabilitiesduewithinoneyear | 619,613,745.74 | 611,917,847.37 |
| Othercurrentliabilities | 810,273.49 | 749,710.19 |
| Totalcurrentliabilities | 19,173,615,770.50 | 16,963,931,157.40 |
| Non-currentliabilities: | ||
| Insurancecontractreserve | ||
| Long-termborrowings | ||
| Bondspayable | ||
| Including:Preferredstock | ||
| Perpetualcapitalsecurities | ||
| Leaseliabilities | 1,261,824,990.27 | 1,208,453,029.51 |
| Long-termpayables | 800,000.00 | 800,000.00 |
| Long-termemployeebenefitspayable | 1,433,000.00 | 1,433,000.00 |
| Accrualliability | ||
| Deferredincome | 87,487,310.49 | 88,704,272.88 |
| Deferredtaxliabilities | 180,619,768.58 | 118,704,213.68 |
| Othernon-currentliabilities | 391,784,710.75 | 73,256,514.93 |
| Totalnon-currentliabilities | 1,923,949,780.09 | 1,491,351,031.00 |
| Totalliabilities | 21,097,565,550.59 | 18,455,282,188.40 |
| Owner’sequity: | ||
| Sharecapital | 428,126,983.00 | 428,126,983.00 |
| Otherequityinstrument | ||
| Including:Preferredstock | ||
| Perpetualcapitalsecurities | ||
| Capitalsurplus | 4,372,907,637.11 | 4,470,766,959.44 |
| Less:Inventoryshares | ||
| Othercomprehensiveincome | 45,909,846.02 | 45,917,342.77 |
| Reasonablereserve | ||
| Surplusreserves | 214,063,491.50 | 214,063,491.50 |
| Provisionofgeneralrisk | ||
| Retainedearnings | 8,001,632,303.78 | 7,752,831,647.90 |
| Shareholders’equityattributabletoshareholdersoftheparent | 13,062,640,261.41 | 12,911,706,424.61 |
| Non-controllinginterests | 2,722,434,868.62 | 2,663,531,604.81 |
| Totalshareholders’equity | 15,785,075,130.03 | 15,575,238,029.42 |
| Totalliabilitiesandshareholders’equity | 36,882,640,680.62 | 34,030,520,217.82 |
LegalRepresentative:LinZhaoxiongPersoninchargeofaccountingworks:WeiPingxiaoPersoninchargeofaccountinginstitute:WangYing
2.BalanceSheetofParentCompany
InRMB
| Item | 2020-3-31 | 2019-12-31 |
| Currentassets: | ||
| Cashandbankbalances | 2,822,146,959.33 | 2,909,417,289.71 |
| Tradingfinancialassets | ||
| Derivativefinancialassets | ||
| Notesreceivable | 12,331,708.43 | 14,900,068.42 |
| Accountsreceivable | 594,814,676.12 | 571,544,784.65 |
| Receivablefinancing | 3,377,820.85 | 30,194,682.11 |
| Advancestosuppliers | 13,142,791.24 | 7,996,243.28 |
| Otherreceivables | 2,084,765,484.28 | 1,928,941,595.38 |
| Including:Interestreceivable | ||
| Dividendreceivable | 834,914.61 | 834,914.61 |
| Inventories | 216,005,001.01 | 169,422,075.78 |
| Contractualassets | ||
| Assetsheldforsale | ||
| Non-currentassetsmaturingwithinoneyear | ||
| Othercurrentassets | 39,482.38 | 39,482.38 |
| Totalcurrentassets | 5,746,623,923.64 | 5,632,456,221.71 |
| Non-currentassets: | ||
| Debtinvestment | ||
| Otherdebtinvestment | ||
| Long-termreceivables | ||
| Long-termequityinvestments | 7,736,253,202.12 | 7,698,756,525.83 |
| Investmentinotherequityinstrument | ||
| Othernon-currentfinancialassets | 140,000,000.00 | 140,000,000.00 |
| Investmentproperties | 1,476,181.93 | 1,484,198.56 |
| Fixedassets | 13,843,610.76 | 14,763,656.62 |
| Constructioninprogress | ||
| Productivebiologicalassets | ||
| Oilandnaturalgasassets | ||
| Right-of-useassets | 5,937,816.70 | 6,217,504.50 |
| Intangibleassets | 5,489,250.88 | 5,838,737.17 |
| Researchanddevelopmentcosts | ||
| Goodwill | ||
| Long-termprepaidexpenses | 5,620,360.05 | 6,130,534.55 |
| Deferredtaxassets | 9,301,194.10 | 9,327,850.53 |
| Othernon-currentassets | 24,058,875.73 | 9,000,000.00 |
| Totalnon-currentassets | 7,941,980,492.27 | 7,891,519,007.76 |
| Totalassets | 13,688,604,415.91 | 13,523,975,229.47 |
| Currentliabilities | ||
| Short-termborrowings | 165,998,444.54 | 121,350,644.36 |
| Tradingfinancialliability |
| Derivativefinancialliability | ||
| Notespayable | 451,394,209.68 | 751,577,900.22 |
| Accountspayable | 353,628,404.84 | 322,436,681.01 |
| Accountsreceivedinadvance | ||
| Contractliabilities | 11,429,537.40 | 7,293,184.46 |
| Employeebenefitspayable | 19,083,766.42 | 30,469,777.88 |
| Taxepayable | 11,257,362.50 | 22,909,124.90 |
| Otherpayables | 2,366,308,945.51 | 2,120,794,765.05 |
| Including:Interestpayable | 509,597.78 | 861,110.53 |
| Dividendpayable | ||
| Liabilityheldforsale | ||
| Non-currentliabilitiesduewithinoneyear | 32,651,734.15 | 32,640,325.77 |
| Othercurrentliabilities | 314,047.05 | 338,196.81 |
| Totalcurrentliabilities | 3,412,066,452.09 | 3,409,810,600.46 |
| Non-currentliabilities: | ||
| Long-termloans | ||
| Bondspayable | ||
| Including:preferredstock | ||
| Perpetualcapitalsecurities | ||
| Leaseliabilities | 5,203,186.76 | 5,461,257.38 |
| Long-termpayables | 800,000.00 | 800,000.00 |
| Longtermemployeecompensationpayable | ||
| Accruedliabilities | ||
| Deferredincome | 1,164,438.54 | 1,276,698.66 |
| Deferredincometaxliabilities | ||
| Othernon-currentliabilities | 90,748,869.74 | |
| Totalnon-currentliabilities | 97,916,495.04 | 7,537,956.04 |
| Totalliabilities | 3,509,982,947.13 | 3,417,348,556.50 |
| Owners’equity: | ||
| Sharecapital | 428,126,983.00 | 428,126,983.00 |
| Otherequityinstrument | ||
| Including:preferredstock |
| Perpetualcapitalsecurities | ||
| Capitalpublicreserve | 4,468,385,307.32 | 4,468,385,307.32 |
| Less:Inventoryshares | ||
| Othercomprehensiveincome | -133,366.19 | -133,366.19 |
| Specialreserve | ||
| Surplusreserves | 214,063,491.50 | 214,063,491.50 |
| Retainedearnings | 5,068,179,053.15 | 4,996,184,257.34 |
| Totalshareholders’equity | 10,178,621,468.78 | 10,106,626,672.97 |
| Totalliabilitiesandshareholders’equity | 13,688,604,415.91 | 13,523,975,229.47 |
3.ConsolidatedProfitStatement
InRMB
| Item | Currentperiod | Lastperiod |
| I.Totaloperatingrevenue | 12,824,196,278.66 | 12,071,656,553.13 |
| Including:operatingrevenue | 12,824,196,278.66 | 12,071,656,553.13 |
| Interestincome | ||
| Insurancegained | ||
| Commissionchargeandcommissionincome | ||
| II.Totaloperatingcosts | 12,488,521,944.35 | 11,708,131,977.39 |
| Including:Operatingcost | 11,370,970,742.96 | 10,734,553,498.15 |
| Interestexpense | ||
| Commissionchargeandcommissionexpense | ||
| Cashsurrendervalue | ||
| Netamountofexpenseofcompensation | ||
| Netamountofwithdrawalofinsurancecontractreserve | ||
| Bonusexpenseofguaranteeslip | ||
| Reinsuranceexpense | ||
| Taxandsurcharges | 29,109,421.79 | 30,631,231.08 |
| Sellingexpenses | 844,624,826.78 | 742,825,433.15 |
| Administrativeexpense | 214,805,866.61 | 184,521,686.12 |
| R&Dexpense |
| Financecosts | 29,011,086.21 | 15,600,128.89 |
| Including:Interestcost | 60,067,901.98 | 44,592,359.04 |
| Interestincome | 29,094,889.11 | 29,675,288.29 |
| Add:otherincomes | 13,133,111.50 | 1,089,732.58 |
| Investmentincome(Lossislistedwith“-”) | 42,676,071.54 | 65,383,095.99 |
| Including:Investmentincomefromassociates | 60,020,272.13 | 81,891,387.17 |
| Incomefromthederecognitionoffinancialassetsmeasuredatamortisedcost | -18,342,866.43 | -16,508,291.18 |
| Exchangeincome(Lossislistedwith“-”) | ||
| Netexposurehedgingincome(Lossislistedwith“-”) | ||
| Incomefromchangeoffairvalue(Lossislistedwith“-”) | ||
| Creditimpairmentlosses(Lossislistedwith“-”) | -16,845,052.13 | -4,399,838.33 |
| Impairmentlosses(Lossislistedwith“-”) | -1,598,436.71 | -516,563.77 |
| Gainondisposalofassets(Lossislistedwith“-”) | -261,264.83 | -14,209.30 |
| III.Operatingprofit(Lossislistedwith“-”) | 372,778,763.68 | 425,066,792.91 |
| Add:Non-operatingincome | 1,811,729.05 | 1,840,452.50 |
| Less:Non-operatingexpenses | 1,710,329.13 | 374,748.81 |
| IV.Totalprofit(Lossislistedwith“-”) | 372,880,163.60 | 426,532,496.60 |
| Less:Incometaxes | 77,791,885.48 | 81,751,622.22 |
| V.Netprofit(Netlossislistedwith“-”) | 295,088,278.12 | 344,780,874.38 |
| (i)Classifybybusinesscontinuity | ||
| 1.Netprofitfromcontinuousoperation(netlosslistedwith‘-”) | 295,088,278.12 | 344,780,874.38 |
| 2.Netprofitfromdiscontinuedoperation(netlosslistedwith‘-”) | ||
| (ii)Classifybyownership | ||
| 1.Ownersoftheparent | 248,800,655.88 | 299,451,036.34 |
| 2.Non-controllinginterests | 46,287,622.24 | 45,329,838.04 |
| VI.Netafter-taxofothercomprehensiveincome | ||
| Netafter-taxofothercomprehensiveincomeattributabletoownersofparentcompany | ||
| (I)Othercomprehensiveincomeitemswhichwillnotbereclassifiedsubsequentlytoprofitofloss | ||
| 1.Changesofthedefinedbenefitplansthatre-measured | ||
| 2.Othercomprehensiveincomeunderequitymethodthatcannotbetransfertogain/loss | ||
| 3.Changeoffairvalueofinvestmentinotherequityinstrument | ||
| 4.Fairvaluechangeofenterprise'screditrisk | ||
| 5.Other | ||
| (ii)Othercomprehensiveincomeitemswhichwillbereclassifiedsubsequentlytoprofitorloss | ||
| 1.Othercomprehensiveincomeunderequitymethodthatcantransfertogain/loss | ||
| 2.Changeoffairvalueofotherdebtinvestment | ||
| 3.Amountoffinancialassetsre-classifytoothercomprehensiveincome | ||
| 4.Creditimpairmentprovisionforotherdebtinvestment | ||
| 5.Cashflowhedgingreserve | ||
| 6.Translationdifferencesarisingontranslationofforeigncurrencyfinancialstatements | ||
| 7.Other |
| Netafter-taxofothercomprehensiveincomeattributabletominorityshareholders | ||
| VII.Totalcomprehensiveincome | 295,088,278.12 | 344,780,874.38 |
| Totalcomprehensiveincomeattributabletoshareholdersoftheparent | 248,800,655.88 | 299,451,036.34 |
| Totalcomprehensiveincomeattributabletonon-controllinginterests | 46,287,622.24 | 45,329,838.04 |
| VIII.Earningspershare: | ||
| (i)Basicearningspershare | 0.58 | 0.70 |
| (ii)Dilutedearningspershare | 0.58 | 0.70 |
EnterprisecombineunderthesamecontrolinthePeriod,thecombinedpartyrealizednetprofitof-2,057,252.42Yuanbeforecombination,andrealized1,711,604.94YuanatlastperiodforcombinedpartyLegalRepresentative:LinZhaoxiongPersoninchargeofaccountingworks:WeiPingxiaoPersoninchargeofaccountinginstitute:WangYing
4.ProfitStatementofParentCompany
InRMB
| Item | Currentperiod | Lastperiod |
| I.Operatingrevenue | 883,090,683.07 | 980,473,288.29 |
| Less:Operatingcosts | 850,760,365.77 | 941,804,760.61 |
| Taxandsurcharges | 1,011,193.50 | 1,316,238.98 |
| Sellingexpenses | 16,302,891.84 | 14,925,549.11 |
| Administrativeexpenses | 22,374,408.72 | 14,279,164.82 |
| R&Dexpenses | ||
| Financecosts | -22,842,676.94 | -14,512,152.70 |
| Including:Interestcost | 9,151,290.82 | 9,720,694.28 |
| Interestincome | 32,061,791.21 | 24,381,516.96 |
| Add:otherincomes | 293,056.51 | 193,207.80 |
| Investmentincome(Lossislistedwith“-”) | 60,592,685.27 | 87,255,527.95 |
| Including:Investmentincomefromassociates | 60,134,457.45 | 87,865,487.39 |
| Incomefromthederecognitionoffinancialassetsmeasuredatamortisedcost | -540,438.02 | -609,959.44 |
| Netexposurehedgingincome(Lossislistedwith“-”) | ||
| Changingincomeoffairvalue(Lossislistedwith“-”) | ||
| Creditimpairmentlosses(Lossislistedwith“-”) | -973,888.89 | |
| Impairmentlosses(Lossislistedwith“-”) | 217,422.14 | -361,970.94 |
| Incomeondisposalofassets(Lossislistedwith“-”) | ||
| II.Operatingprofit(Lossislistedwith“-”) | 75,613,775.21 | 109,746,492.28 |
| Add:Non-operatingincome | 1,578.11 | 45,736.26 |
| Less:Non-operatingexpenses | ||
| III.TotalProfit(Lossislistedwith“-”) | 75,615,353.32 | 109,792,228.54 |
| Less:Incometaxes | 3,620,557.51 | 5,482,579.40 |
| IV.Netprofit(Netlossislistedwith“-”) | 71,994,795.81 | 104,309,649.14 |
| (i)Netprofitfromcontinuousoperation(netlosslistedwith‘-”) | 71,994,795.81 | 104,309,649.14 |
| (ii)Netprofitfromdiscontinuedoperation(netlosslistedwith‘-”) | ||
| V.Netafter-taxofothercomprehensiveincome | ||
| (I)Othercomprehensiveincomeitemswhichwillnotbereclassifiedsubsequentlytoprofitofloss | ||
| 1.Changesofthedefinedbenefitplansthatre-measured | ||
| 2.Othercomprehensiveincomeunderequitymethodthatcannotbetransfertogain/loss | ||
| 3.Changeoffairvalueofinvestmentinotherequityinstrument |
| 4.Fairvaluechangeofenterprise'screditrisk | ||
| 5.Other | ||
| (II)Othercomprehensiveincomeitemswhichwillbereclassifiedsubsequentlytoprofitorloss | ||
| 1.Othercomprehensiveincomeunderequitymethodthatcantransfertogain/loss | ||
| 2.Changeoffairvalueofotherdebtinvestment | ||
| 3.Amountoffinancialassetsre-classifytoothercomprehensiveincome | ||
| 4.Creditimpairmentprovisionforotherdebtinvestment | ||
| 5.Cashflowhedgingreserve | ||
| 6.Translationdifferencesarisingontranslationofforeigncurrencyfinancialstatements | ||
| 7.Other | ||
| VI.Totalcomprehensiveincome | 71,994,795.81 | 104,309,649.14 |
| VII.Earningspershare: | ||
| (i)Basicearningspershare | ||
| (ii)Dilutedearningspershare |
5.ConsolidatedCashFlowStatement
InRMB
| Item | Currentperiod | Lastperiod |
| I.Cashflowsfromoperatingactivities: | ||
| Cashreceivedfromsaleofgoodsorrenderingofservices | 13,201,992,638.81 | 11,447,434,730.14 |
| Netincreaseofcustomerdepositandinterbankdeposit | ||
| Netincreaseofloanfromcentralbank |
| Netincreaseofcapitalborrowedfromotherfinancialinstitution | ||
| Cashreceivedfromoriginalinsurancecontractfee | ||
| Netcashreceivedfromreinsurancebusiness | ||
| Netincreaseofinsuredsavingsandinvestment | ||
| Cashreceivedfrominterest,commissionchargeandcommission | ||
| Netincreaseofcapitalborrowed | ||
| Netincreaseofreturnedbusinesscapital | ||
| Netcashreceivedbyagentsinsaleandpurchaseofsecurities | ||
| Receiptsoftaxesandsurchargesrefunds | 775,261.38 | - |
| Othercashreceiptsrelatingtooperatingactivities | 433,415,062.71 | 137,466,777.68 |
| Sub-totalofcashinflowsfromoperatingactivities | 13,636,182,962.90 | 11,584,901,507.82 |
| Cashpaidforgoodsandservices | 12,827,089,312.11 | 11,082,205,912.68 |
| Netincreaseofcustomerloansandadvances | ||
| Netincreaseofdepositsincentralbankandinterbank | ||
| Cashpaidfororiginalinsurancecontractcompensation | ||
| Netincreaseofcapitallent | ||
| Cashpaidforinterest,commissionchargeandcommission | ||
| Cashpaidforbonusofguaranteeslip | ||
| Cashpaidtoandonbehalfofemployees | 703,922,606.95 | 594,165,778.91 |
| Cashpaidforalltypesoftaxes | 368,976,475.15 | 328,266,367.46 |
| Othercashpaymentsrelatingtooperatingactivities | 424,468,417.32 | 368,641,736.27 |
| Sub-totalofcashoutflowsfromoperatingactivities | 14,324,456,811.53 | 12,373,279,795.32 |
| Netcashflowsfromoperatingactivities | -688,273,848.63 | -788,378,287.50 |
| II.Cashflowsfrominvestingactivities: | ||
| Cashreceivedfromrecoveringinvestment | ||
| Cashreceivedfromreturnsoninvestments | 1,053,000.00 | |
| Netcashreceivedfromdisposaloffixedassets,intangibleassetsandotherlong-termassets | 107,430.91 | 72,078.73 |
| Netcashreceivedfromdisposalofsubsidiariesandotherunits | ||
| Othercashreceiptsrelatingtoinvestingactivities | 22,000,000.00 | 188,500,000.00 |
| Sub-totalofcashinflowsfrominvestingactivities | 22,107,430.91 | 189,625,078.73 |
| Cashpaidforacquisitionoffixedassetsintangibleassetsandotherlong-termassets | 50,207,587.50 | 54,074,916.12 |
| Cashpaymentsforinvestments | 11,341,032.15 | 20,122,074.00 |
| Netincreaseofmortgagedloans | ||
| Netcashpaidforacquisitionofsubsidiariesandotherbusinessunits | 664,882,681.20 | |
| Othercashpaymentsrelatingtoinvestingactivities | 41,364,521.11 | 157,902,761.38 |
| Sub-totalofcashoutflowsfrominvestingactivities | 767,795,821.96 | 232,099,751.50 |
| Netcashflowsfrominvestingactivities | -745,688,391.05 | -42,474,672.77 |
| III.Cashflowsfromfinancingactivities | ||
| Cashproceedsfrominvestmentsbyothers | 4,392,000.00 | |
| Including:Cashproceedsfromsubsidiaryinvestmentsbynon-controllingshareholders | 4,392,000.00 | |
| Cashreceivedfromborrowings | 286,202,002.73 | 10,000,000.00 |
| Othercashreceiptsrelatingtofinancingactivities | 337,054,182.02 | 198,881,105.78 |
| Sub-totalofcashinflowsfromfinancingactivities | 623,256,184.75 | 213,273,105.78 |
| Cashrepaymentsfordebts | 142,100,000.00 | 66,561,634.53 |
| Cashpaymentsfordistributionofdividendsorprofitandinterestexpenses | 64,675,017.27 | 84,732,347.73 |
| Including:Profitanddividendspaidtonon-controllingshareholdersofsubsidiaries | 1,558,470.71 | |
| Othercashpaymentsrelatingtofinancingactivities | 473,597,592.59 | 31,976,889.98 |
| Sub-totalofcashoutflowsfromfinancingactivities | 680,372,609.86 | 183,270,872.24 |
| Netcashflowsfromfinancingactivities | -57,116,425.11 | 30,002,233.54 |
| IV.effectofforeignexchangeratechangesoncashandcashequivalents | 365.20 | 605.19 |
| V.Netincreaseofcashandcashequivalents | -1,491,078,299.59 | -800,850,121.54 |
| Add:Cashandcashequivalentsatbeginningoftheyear | 8,426,071,170.16 | 7,644,975,994.75 |
| VI.Cashandcashequivalentsatendofyear | 6,934,992,870.57 | 6,844,125,873.21 |
6.CashFlowStatementofParentCompany
InRMB
| Item | Currentperiod | Lastperiod |
| I.Cashflowsfromoperatingactivities: | ||
| Cashreceivedfromsaleofgoodsorrenderingofservices | 1,062,518,589.11 | 979,117,418.50 |
| Receiptsoftaxesandsurchargesrefunds | ||
| Othercashreceiptsrelatingtooperatingactivities | 22,736,474.18 | 8,959,448.01 |
| Sub-totalofcashinflowsfromoperatingactivities | 1,085,255,063.29 | 988,076,866.51 |
| Cashpaidforgoodsandservices | 1,207,589,273.35 | 893,485,571.99 |
| Cashpaidtoandonbehalfofemployees | 39,968,369.74 | 31,401,584.94 |
| Cashpaidforalltypesoftaxes | 20,509,993.91 | 16,046,448.54 |
| Othercashpaymentsrelatingtooperatingactivities | 14,820,413.79 | 9,310,459.60 |
| Sub-totalofcashoutflowsfromoperatingactivities | 1,282,888,050.79 | 950,244,065.07 |
| Netcashflowsfromoperatingactivities | -197,632,987.50 | 37,832,801.44 |
| II.Cashflowsfrominvestingactivities: | ||
| Cashreceivedfromrecoveringinvestment | 13,636,447.00 | |
| Cashreceivedfromreturnsoninvestments | 16,895,775.01 | |
| Netcashreceivedfromdisposaloffixed,intangibleandotherlong-termassets | ||
| Netcashreceivedfromdisposalofsubsidiariesandotherunits | ||
| Othercashreceiptsrelatingtoinvestingactivities | 602,709,245.48 | 442,400,000.00 |
| Sub-totalofcashinflowsfrominvestingactivities | 616,345,692.48 | 459,295,775.01 |
| Cashpaidforacquisitionoffixedassetsintangibleassetsandotherlong-termassets | 670,760.44 | 1,462,422.93 |
| Cashpaidforinvestment | ||
| Netcashreceivedfromsubsidiariesandotherunitsobtained | ||
| Othercashpaymentsrelatingtoinvestingactivities | 792,214,521.11 | 629,400,000.00 |
| Sub-totalofcashoutflowsfrominvestingactivities | 792,885,281.55 | 630,862,422.93 |
| Netcashflowsfrominvestingactivities | -176,539,589.07 | -171,566,647.92 |
| III.Cashflowsfromfinancingactivities | ||
| Cashreceivedfromabsorbinginvestment | ||
| Cashreceivedfromborrowings | 24,694,789.52 | 10,000,000.00 |
| Othercashreceiptsrelatingtofinancingactivities | 8,004,663,212.88 | 4,517,196,050.81 |
| Sub-totalofcashinflowsfromfinancingactivities | 8,029,358,002.40 | 4,527,196,050.81 |
| Cashrepaymentsfordebts | 12,100,000.00 | 10,000,000.00 |
| Cashpaymentsfordistributionofdividendsorprofitandinterestexpenses | 9,363,675.10 | 6,245,437.77 |
| Othercashpaymentsrelatingtofinancingactivities | 7,724,025,779.65 | 4,584,325,273.13 |
| Sub-totalofcashoutflowsfromfinancingactivities | 7,745,489,454.75 | 4,600,570,710.90 |
| Netcashflowsfromfinancingactivities | 283,868,547.65 | -73,374,660.09 |
| IV.effectofforeignexchangeratechangesoncashandcashequivalents | 365.20 | 605.19 |
| V.Netincreaseofcashandcashequivalents | -90,303,663.72 | -207,107,901.38 |
| Add:Cashandcashequivalentsatbeginningoftheyear | 2,894,333,956.38 | 1,817,654,598.01 |
| VI.Cashandcashequivalentsatendofyear | 2,804,030,292.66 | 1,610,546,696.63 |
II.Explanationonfinancialstatementadjustment
1.Financialstatementadjustmentatthebeginningofthefirstyearwhenimplementationofnewrevenuerulesandnewleasingrulesfrom2020
□Applicable√Notapplicable
2.Retrospectiveadjustmentofthecomparativedataforinitialimplementationofnewrevenuerulesandnewleasingrulesfrom2020
□Applicable√NotapplicableIII.AuditreportWhetherthe1
stquarterlyreporthasbeenauditedornot
□Yes√No1QreportoftheCompanyisunaudited.
ChinaNationalAccordMedicinesCorporationLtd.
Legalrepresentative:LinZhaoxiong
25April2020